{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"1.0","value":"0.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"189"}],"units":"Participants"}],"description":"Event-free survival was calculated from the start date of blinatumomab infusion until the date of bone marrow aspiration at which hematological relapse was first detected, or the date of diagnosis on which the hematological or extramedullary relapse was documented or the date of start of any new therapy for ALL (excluding HSCT), or the date of death, whichever was earlier. Participants who did not achieve complete remission or complete remission with partial hematological recovery during the core study were evaluated as having an event on Day 1. Participants in remission who did not experience hematological relapse, did not receive a new therapy for ALL (excluding HSCT), and did not die were censored on the date of the last available bone marrow aspiration or on the last date of survival follow-up visit, whichever was later.\n\nEvent free survival was estimated using Kaplan-Meier methods and the median observation time was calculated by the reverse Kaplan Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 9 μg/day for the first seven days of treatment, escalated to 28 μg/day starting from Week 2 of treatment.","id":"OG000","title":"Blinatumomab"}],"paramType":"MEDIAN","populationDescription":"Primary analysis set","reportingStatus":"POSTED","timeFrame":"Up to the data cut-off date of 10 October 2013; median observation time was 9.8 months.","title":"Event-free Survival","type":"SECONDARY","unitOfMeasure":"months"}